Barclays Updating Quarterly Estimates for 2017 Seasonality for Express Scripts Holding Company (ESRX)

The firm lowered its 2Q17 EPS estimate to $1.64 from $1.69 while increasing its Q3 and Q4 estimates

Sarepta Therapeutics Inc (NASDAQ:SRPT) Presents Long Term Data on Benefits Of Exondys 51

Clinical trial data for patients on drug for less than one year is not very compelling (clinical benefit not seen by FDA), long-term data (>4 years) on cardiac and pulmonary complications demonstrates the drug slowing progression

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Shares Continue To Decline: Here's What to Do

Investors advised to hold the shares as Valeant steps up its refinancing efforts to acquire additional flexibility

Intercept Pharmaceuticals (NASDAQ:ICPT): Weekly Symphony Health Ocaliva Sales and Volume Estimates

For the week ended March 17, Symphony Health sales and volume estimates for Ocaliva were slightly more than $2MM and just over 355 pack units (both up ~33% w/w), respectively

TESARO Inc's (TSRO) Strong Prospects in Immuno-Oncology: Argus

Tesaro is preparing for four commercial launches in 2017, and plans to initiate pivotal studies this year for several products in the emerging area of immuno-oncology

Gilead Sciences, Inc. (GILD) Cutting Estimates on Declining Hep C Sales: Argus

Gilead projects 2017 worldwide hep C product sales of $7.5-$9.0 billion, down from $14.32 billion in 2016